Business Wire

Computer Vision Technology Delivered by Johnson Controls Sensormatic Solutions Powers a Portfolio of Outcome-Focused Analytics to Solve Retailers’ Evolving Challenges

Share

Sensormatic Solutions, the leading global retail solutions portfolio of Johnson Controls, is demonstrating the full breadth of its computer vision analytics technology at EuroShop. Each of Sensormatic Solutions computer vision capabilities leverage proprietary deep learning algorithms and help retailers optimize labor allocation, strengthen loss prevention efforts, maintain safe environments for shoppers and associates, and gather insights on shopper experiences.

“Despite the technology’s relatively short time on the market, we’ve evolved its capabilities significantly, taking it from simple object detection to using complex behavior detection to identify and analyze shopper behavior,” said Subramanian Kunchithapatham (KS), chief technology officer at Sensormatic Solutions. “Computer vision’s unparalleled insights give retailers the power to enhance the store experience by automating specific tasks, which allow store associates to focus on valuable customer interactions.”

Maximize Conversion Opportunities with Shopper Engagement

Computer vision’s newest outcome-focused capabilities are designed to help retailers leverage shopper behavior data to improve conversion and optimize merchandise placement and floor design by leveraging in-store path-to-purchase pattern insights. The technology can also recognize impactful marketing partnership opportunities by identifying consumers’ buying choices and brand preferences throughout their journey.

Driving Operational Excellence by Allocating Labor to the Right Place at the Right Time

With labor shortages, computer vision analytics automates associate tasks and provides powerful insights that can help retailers identify the times and areas in which associates are most needed to help enhance the customer experience and drive sales, while reducing labor expenses.

With the popularity of omnichannel fulfillment options, like Click & Collect and curbside pick-up, retailers are seeking ways to fill these orders while minimizing labor hours spent searching for merchandise. Computer vision analytics enables exterior parking lot cameras to detect the arrival of customers to pre-determined areas, alerting associate in real-time to fulfill or deliver an order.

Insights Amplify Proactive Loss Prevention and Liability Programs

Computer vision can amplify solutions used today to help mitigate shrink by enabling more proactive and preventative measures to deter theft, detect Organized Retail Crime (ORC) activity, and help protect people and assets through real-time monitoring of suspicious and criminal behavior.

Sensormatic Solutions computer vision technology leverages existing video infrastructure investments and is easy to deploy. "While many retailers already depend on cameras for surveillance, they can now leverage our computer vision analytics by tapping into that same infrastructure to unlock a world of new capabilities that help drive sales, reduce risk, optimize labor and enhance the customer experience," continued Kunchithapatham.

To learn more about Sensormatic Solutions computer vision analytics, visit stand C01 in Hall 6 at Trade Fair Düsseldorf between 26 February – 2 March 2023 and follow #Sensormatic on Twitter and LinkedIn. To request a booth tour or a meeting with an account manager, visit the Sensormatic Solutions EuroShop Page.

About Johnson Controls

At Johnson Controls (NYSE:JCI), we transform the environments where people live, work, learn and play. As the global leader in smart, healthy and sustainable buildings, our mission is to reimagine the performance of buildings to serve people, places and the planet.

Building on a proud history of nearly 140 years of innovation, we deliver the blueprint of the future for industries such as healthcare, schools, data centers, airports, stadiums, manufacturing and beyond through OpenBlue, our comprehensive digital offering.

Today, with a global team of 100,000 experts in more than 150 countries, Johnson Controls offers the world`s largest portfolio of building technology and software as well as service solutions from some of the most trusted names in the industry.

Visit http://www.johnsoncontrols.com for more information and follow @Johnson Controls on social platforms.

About Sensormatic Solutions

Sensormatic Solutions is the leading global retail solutions portfolio of Johnson Controls powering operational excellence at scale and enabling smart and connected shopper engagement. Our intelligent digital operating platform – Sensormatic IQ – combines the full Sensormatic Solutions portfolio, including third-party data to deliver unmatched insights into shopper experience, inventory intelligence, loss prevention and operational effectiveness with advanced technologies, like AI and Machine Learning. This enables retailers to act on prescriptive and predictive data-driven outcomes to confidently move into the future. Please visit Sensormatic Solutions or follow us on LinkedIn, Twitter, and our YouTube channel.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Katarzyna Breczko
Sensormatic Solutions by Johnson Controls
Work: +49 173 7070 562
katarzyna.breczko@jci.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release

Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye